Study clarifies best treatments for uncommon kidney cancers
the ONA take:
Researchers at Duke Cancer Institute led a study comparing two biologic therapies used to treat a subset of advanced kidney cancers.
The head-to-head comparison offers clinicians much-needed clarity on the preferred first-line treatment of these cancers.
The study focused on three form of non-clear cell kidney cancers: metastatic papillary, chromophobe, or unclassified. In the study, 108 patients were randomly assigned to receive either everolimus or sunitinib, the two treatments approved for these cancers, until their tumors progressed.
The findings show that sunitinib was superior overall at prolonging the time to tumor regrowth, but at a higher rate of severe toxicity.
Sunitinib was also more effective for papillary-type kidney cancers and for better prognosis patients. Everolimus offered longer median progression-free survival for patients with chromophobe and poor-risk tumors.
In addition, more than 100 study participants donated tumor tissue. The researchers now have the largest repository of non-clear cell kidney cancer tissue to aid in further research toward developing new drugs and identifying biomarkers for the disease.
Head-to-head comparison offers clinicians much-needed clarity on the preferred first-line treatment of kidney cancers.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|